Safety and efficacy of Glucagon-Like Peptide 1 Receptor Agonist and Sodium Glucose Transporter 2 inhibitor on major limb adverse events and mortality in peripheral artery disease and diabetes
In a retrospective cohort study of over 13,000 patients with peripheral artery disease and diabetes, combined treatment with GLP-1 receptor agonists and SGLT2 inhibitors was associated with significantly reduced risks of major adverse limb events, amputations, and all-cause mortality compared to no treatment, with SGLT2 inhibitors also showing similar benefits while GLP-1 receptor agonist monotherapy demonstrated a survival advantage.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people living with diabetes, the threat of poor circulation is a constant shadow. When high blood sugar damages the delicate network of vessels that carry life-giving oxygen to the limbs, a condition known as peripheral artery disease can take hold. This is not merely a matter of aching legs; it is a severe blockage that can starve the feet and lower legs of blood, leading to tissue death, non-healing wounds, and in the most tragic cases, the loss of a limb. For decades, doctors have relied on a standard toolkit of medications to manage the underlying diabetes and protect the heart, but a specific question has lingered in the medical community: do the newer, powerful drugs designed to lower blood sugar also protect the legs from this specific kind of disaster? Two classes of modern medications, known as GLP-1 receptor agonists and SGLT2 inhibitors, have revolutionized diabetes care by proving they can save lives and prevent heart attacks. Yet, their specific ability to keep limbs intact in patients with severe artery disease has remained a mystery, with some early, isolated concerns suggesting they might even increase the risk of amputation.
To answer this, a team of researchers from Israel and Palestine turned to a massive digital archive of real-world patient history. They looked at the medical records of 13,471 adults who had both diabetes and peripheral artery disease. These patients were tracked over a period of nearly six years, a timeframe long enough to see who developed new blockages, who required surgery to restore blood flow, and who faced the ultimate tragedy of amputation or death. The researchers did not just look at who took which pill; they carefully grouped the patients into four distinct categories: those who took neither of the new drugs, those who took only the first type, those who took only the second type, and those who took both together. By using advanced statistical methods to balance the groups—ensuring that differences in age, weight, and other health factors did not skew the results—they could isolate the true effect of the medications.
The findings paint a clear and reassuring picture for patients facing this difficult diagnosis. Those who received treatment with both medications together saw the most dramatic benefits. Compared to patients who received neither drug, the group taking both therapies was half as likely to suffer a major adverse limb event, a term that encompasses the need for emergency surgery to bypass a blockage or the loss of a limb. The risk of a major amputation, defined as the removal of a foot or leg above the ankle, dropped even further, to just 30 percent of the risk seen in the untreated group. Perhaps most striking was the impact on survival; patients on the combined therapy were far less likely to die from any cause during the study period, with their risk of death dropping to less than a quarter of that seen in the untreated group.
The data also offered clarity on the individual drugs. Patients who took only the SGLT2 inhibitor saw a similar, though slightly less pronounced, reduction in the risk of losing a limb or needing surgery. This result is particularly significant because it directly addresses earlier fears that these drugs might harm the legs. The study found no evidence of increased danger; instead, it suggested a protective effect that aligns with the drug's ability to improve blood flow and vessel health. The patients taking only the GLP-1 receptor agonist also lived longer than those on no treatment, showing a strong survival benefit, though the numbers for limb-specific outcomes in this smaller group were too limited to draw the same firm conclusions as the other groups.
When the researchers mapped out the journey of these patients over time, the separation between the treated and untreated groups became visually obvious. The curves representing the untreated patients climbed steadily, showing a rising tide of amputations and deaths, while the lines for those on medication, especially the combination, remained remarkably flat. This suggests that the drugs are not just managing blood sugar numbers but are actively preserving the integrity of the vascular system. The study authors note that while these results are based on observation and cannot prove cause and effect with the absolute certainty of a controlled experiment, the consistency of the data across thousands of patients and multiple years of follow-up is compelling. The research provides strong evidence that for patients with both diabetes and clogged arteries, the combination of these two modern therapies offers a powerful shield, keeping limbs safe and extending lives in ways that standard care alone has not achieved.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.